Comparative Pharmacology
Head-to-head clinical analysis: ANDROID F versus DELATESTRYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID F versus DELATESTRYL.
ANDROID-F vs DELATESTRYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fingolimod is a sphingosine 1-phosphate receptor modulator that sequesters lymphocytes in lymph nodes, reducing central nervous system immune cell infiltration.
Testosterone ester; binds to androgen receptors, activating gene transcription and promoting protein synthesis, muscle growth, and secondary sexual characteristics.
Adults: 1 tablet (methyltestosterone 2.5 mg, ethinyl estradiol 0.025 mg) orally once daily, with food.
50 to 200 mg intramuscularly every 2 to 4 weeks.
None Documented
None Documented
2.5-3.5 hours (terminal half-life); oral administration may require multiple daily doses for stable levels.
8 days (terminal); requires 5-6 weeks to reach steady state with weekly dosing
Primarily renal (90% as glucuronide and sulfate conjugates, 10% unchanged); small amount biliary/fecal.
Urinary (90% as glucuronide and sulfate conjugates, 5% as unchanged drug); fecal (5%)
Category C
Category C
Androgen/Estrogen Combination
Androgen